Endometrial Hyperplasia and Endometrial Cancers Clinical Trial
Official title:
Role of Senescence in the Development of Endometrial Cancer
| Verified date | January 2018 |
| Source | CHU de Reims |
| Contact | Emilie RAIMOND |
| Phone | 0326789598 |
| eraimond[@]chu-reims.fr | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Several molecular studies showed chromosomal alterations in patients with endometrial cancer,
with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of
interest have been identified (P53, PTEN, PIK3CA, ß-catenin, K-ras ...).
A study has already been carried out at the Reims University Hospital with inclusion of
patients with endometrial cancer and patients with endometrial hyperplasia. It identified
specific alterations of nosologic continuum of pathology and characterize areas of interest
on the genome.
| Status | Recruiting |
| Enrollment | 140 |
| Est. completion date | April 16, 2020 |
| Est. primary completion date | October 16, 2019 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - patient with endometrial hyperplasia or endometrial cancer - patient consenting to participate to the study - patient enrolled in the national healthcare insurance program - patient older than 18 years Exclusion Criteria: - patient with neoadjuvant chemotherapy or radiotherapy prior to surgery |
| Country | Name | City | State |
|---|---|---|---|
| France | Damien JOLLY | Reims |
| Lead Sponsor | Collaborator |
|---|---|
| CHU de Reims |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Genetic imbalances | Genetic aberrations detected by comparative genomic hybridization (CGH arry) | Day 0 |